Differential integrin expression by T lymphocytes: Potential role in DMD muscle damage

Journal of Neuroimmunology

Volumn 223, Issue 1-2, 2010, Pages 128-130

  Pinto Mariz, Fernanda ^a,b,c   Rodrigues Carvalho, Luciana ^a   de Mello, Wallace ^a,d   de Queiroz Campos Araújo, Alexandra ^b   Gonçalves Ribeiro, Márcia ^b   do Carmo Soares Alves Cunha, Maria ^b   Voit, Thomas ^c   Butler Browne, Gillian ^c   Silva Barbosa, Suse Dayse ^a   Savino, Wilson ^a  

^a INSTITUTO OSWALDO CRUZ   (Brazil)

^b FEDERAL UNIVERSITY OF RIO DE JANEIRO   (Brazil)

^c SORBONNE UNIVERSITÉ   (France)

^d National Institute of Traumatology and Orthopaedics NITO   (Brazil)

Author keywords

Cell migration; Duchenne muscular dystrophy; Fibronectin; Integrins; T lymphocytes

Indexed keywords

FIBRONECTIN; INTEGRIN; LAMININ RECEPTOR; VERY LATE ACTIVATION ANTIGEN 4; VERY LATE ACTIVATION ANTIGEN 5; VERY LATE ACTIVATION ANTIGEN 6;

ARTICLE; CD3+ T LYMPHOCYTE; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELL MIGRATION; CONTROLLED STUDY; DUCHENNE MUSCULAR DYSTROPHY; EXTRACELLULAR MATRIX; HUMAN; HUMAN CELL; IMMUNOPHENOTYPING; LYMPHOCYTE SUBPOPULATION; MUSCLE INJURY; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; T LYMPHOCYTE; TISSUE INJURY;

ADOLESCENT; CELL MOVEMENT; CHILD; CHILD, PRESCHOOL; GENE EXPRESSION REGULATION; HUMANS; IMMUNOPHENOTYPING; INTEGRIN ALPHA CHAINS; INTEGRIN ALPHA5BETA1; INTEGRIN ALPHA6BETA1; INTEGRINS; MUSCLE, SKELETAL; MUSCULAR DYSTROPHY, DUCHENNE; T-LYMPHOCYTE SUBSETS;

EID: 77953544020     PISSN: 01655728     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jneuroim.2010.03.006     Document Type: Article

References (16)

1. Banks G.B., Chamberlain J.S. The value of mammalian models for duchenne muscular dystrophy in developing therapeutic strategies. Curr. Top. Dev. Biol. 2008, 84:431-453.
2. Friedl P., Weigelin B. Interstitial leukocyte migration and immune function. Nat. Immunol. 2008, 9:960-969.
3. Gussoni E., Pavlath G.K., Miller R.G., Panzara M.A., Powell M., Blau H.M., Steinman L. Specific T cell receptor gene rearrangements at the site of muscle degeneration in Duchenne muscular dystrophy. J. Immunol. 1994, 153:4798-4805.
4. Hussein M.R., Hamed S.A., Mostafa M.G., Abu-Dief E.E., Kamel N.F., Kandil M.R. The effects of glucocorticoid therapy on the inflammatory and dendritic cells in muscular dystrophies. Int. J. Exp. Pathol. 2006, 87:451-461.
5. Kissel J.T., Burrow K.L., Rammohan K.W., Mendell J.R. Mononuclear cell analysis of muscle biopsies in prednisone-treated and untreated Duchenne muscular dystrophy. Neurology 1991, 41:667-672. CIDD Study Group.
6. Kissel J.T., Lynn D.J., Rammohan R.W., Klein J.P., Griggs R.C., Moxley R.T., Cwick V.A., Brooke M.H., Mendell J.R. Mononuclear cells analysis of muscle biopsies in prednisone and azathioprine-treated Duchenne muscular dystrophy. Neurology 1993, 43:532-536.
7. Lagrota-Cândido J., Canella I., Savino W., Quirico-Santos T. Expression of extracellular matrix ligands and receptors in the muscular tissue and draining lymph nodes of mdx dystrophic mice. Clin. Immunol. 1999, 93:143-151.
8. Miller D.H., Khan O.A., Sheremata W.A., Blumhardt L.D., Rice G.P., Libonati M.A., Willmer-Hulme A.J., Dalton C.M., Miszkiel K.A., O'Connor P.W. International Natalizumab Multiple Sclerosis Trial Group. A controlled trial of natalizumab for relapsing multiple sclerosis. N. Engl. J. Med. 2003, 348:15-23.
9. Rampoldi E., Meola G., Conti A.M., Velicogna M., Larizza L. A comparative analysis of collagen III, IV, laminin and fibronectin in Duchenne muscular dystrophy biopsies and cell cultures. Eur. J. Cell Biol. 1986, 42:27-34.
10. Sandborn W.J., Colombel J.F., Enns R., Feagan B.G., Hanauer S.B., Lawrance I.C., Panaccione R., Sanders M., Schreiber S., Targan S., van Deventer S., Goldblum R., Despain D., Hogge G.S., Rutgeerts P. Evaluation of Natalizumab as Continuous Therapy (ENACT-2) Trial Group. Natalizumab induction and maintenance therapy for Crohn's disease. N. Engl. J. Med. 2005, 353:1912-1925. International Efficacy of Natalizumab as Active Crohn's Therapy (ENACT-1) Trial Group.
11. Silva-Barbosa S.D., Savino W. The involvement of laminin in anti-myocardial cell autoimmune response in Chagas disease. Dev. Immunol. 2000, 7:293-301.
12. Silva-Barbosa S.D., Butler-Browne G.S., Di Santo J.P., Mouly V. Comparative analysis of genetically engineered immunodeficient mouse strains as recipients for human myoblast transplantation. Cell Transplant. 2005, 14:457-467.
13. Smaniotto S., Mello-Coelho V., Villa-Verde D.M.S., Pléau J.M., Postel-Vinay M.C., Dardenne M., Savino W. Growth hormone modulates thymocyte development in vivo through a combined action of laminin and CXCL12. Endocrinology 2005, 146:3005-3017.
14. Spencer M.J., Tidball J.G. Do immune cells promote the pathology of dystrophin-deficient myopathies?. Neuromuscul. Disord. 2001, 11:556-564.
15. Spencer M.J., Walsh C.M., Dorshkind K.A., Rodriguez E.M., Tidball J.G. Myonuclear apoptosis in dystrophic mdx muscle occurs by perforin-mediated cytotoxicity. J. Clin. Invest 1997, 99:2745-2751.
16. Vainzof M., Ayub-Guerrieri D., Onofre P.C., Martins P.C., Lopes V.F., Zilberztajn D., Maia L.S., Sell K., Yamamoto L.U. Animal models for genetic neuromuscular diseases. J. Mol. Neurosci. 2008, 34:241-248.